Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer

Molecular Biology of the Cell

Volumn 26, Issue 22, 2015, Pages 4087-4099

  Valley, Christopher C ^a   Arndt Jovin, Donna J ^b   Karedla, Narain ^c   Steinkamp, Mara P ^a   Chizhik, Alexey I ^c   Hlavacek, William S ^d   Wilson, Bridget S ^a   Lidke, Keith A ^e   Lidke, Diane S ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d LOS ALAMOS NATIONAL LABORATORY   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND; PHOSPHOTRANSFERASE; QUANTUM DOT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR DERIVATIVE; PROTEIN AGGREGATE; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CHO CELL LINE; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVATION; FLUORESCENCE IMAGING; FLUORESCENCE RESONANCE ENERGY TRANSFER; LIGAND BINDING; MOLECULAR IMAGING; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RECEPTOR DENSITY; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CELL PROLIFERATION; CELL TRANSFORMATION; CONFOCAL MICROSCOPY; CRICETULUS; ENZYMOLOGY; GENETICS; HELA CELL LINE; HUMAN; LUNG TUMOR; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; PROTEIN MULTIMERIZATION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHO CELLS; CRICETULUS; EGF FAMILY OF PROTEINS; HELA CELLS; HUMANS; LUNG NEOPLASMS; MICROSCOPY, CONFOCAL; MUTATION; PHOSPHORYLATION; PROTEIN AGGREGATES; PROTEIN KINASE INHIBITORS; PROTEIN MULTIMERIZATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84946771788     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E15-05-0269     Document Type: Article

References (89)

1. Abulrob A, Lu Z, Baumann E, Vobornik D, Taylor R, Stanimirovic D, Johnston LJ (2010). Nanoscale imaging of epidermal growth factor receptor clustering: effects of inhibitors. J Biol Chem 285, 3145-3156.
2. Alvarado D, Klein DE, Lemmon MA (2010). Structural basis for negative cooperativity in growth factor binding to an EGF receptor. Cell 142, 568-579.
3. Arkhipov A, Shan Y, Das R, Endres NF, Eastwood M P, Wemmer DE, Kuriyan J, Shaw DE (2013). Architecture and membrane interactions of the EGF receptor. Cell 152, 557-569.
4. Bessman NJ, Lemmon MA (2012). Finding the missing links in EGFR. Nat Struct Mol Biol 19, 1-3.
5. Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J (1997). PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 3, 2099-2106.
6. Bremer EG, Schlessinger J, Hakomori S (1986). Ganglioside-mediated modulation of cell growth. Specifc effects of GM3 on tyrosine phos-phorylation of the epidermal growth factor receptor. J Biol Chem 261, 2434-2440.
7. Burgess AW, Cho H, Eigenbrot C, Ferguson KM, Garrett TP J, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S (2003). An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12, 541-552.
8. Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, Park F, Haley JD, Gibson N, Sliwkowski MX (2006). Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, Erlotinib. Cancer Res 66, 8163-8171.
9. Carraway KL, Koland JG, Cerione RA (1989). Visualization of epidermal growth factor (EGF) receptor aggregation in plasma membranes by fuo-rescence resonance energy transfer. Correlation of receptor activation with aggregation. J Biol Chem 264, 8699-8707.
10. Cho J, Chen L, Sangji N, OkabeT, Yonesaka K, Francis JM, Flavin RJ, Johnson W, Kwon J, Yu S, et al. (2013). Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res 73, 6770-6779.
11. Choi SH, Mendrola JM, Lemmon MA (2007). EGF-independent activation of cell-surface EGF receptors harboring mutations found in Geftinib-sensitive lung cancer. Oncogene 26, 1567-1576.
12. Chung I, Akita R, Vandlen R, Toomre D, Schlessinger J, Mellman I (2010). Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature 464, 783-787.
13. Clayton AHA, Walker F, Orchard SG, Henderson C, Fuchs D, Rothacker J, Nice EC, Burgess AW (2005). Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-a multidimensional microscopy analysis. J Biol Chem 280, 30392-30399.
14. Coskun Ü, Grzybek M, Drechsel D, Simons K (2011). Regulation of human EGF receptor by lipids. Proc Natl Acad Sci USA 108, 9044-9048.
15. Dahan M, Lévi S, Luccardini C, Rostaing P, Riveau B, Triller A (2003). Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking. Science 302, 442-445.
16. Dawson J P, Berger MB, Lin C, Schlessinger J, Lemmon MA, Ferguson KM (2005). Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol 25, 7734-7742.
17. De Keijzer S, Sergé A, van Hemert F, Lommerse PHM, Lamers GEM, Spaink H P, Schmidt T, Snaar-Jagalska BE (2008). A spatially restricted increase in receptor mobility is involved in directional sensing during Dictyostelium discoideum chemotaxis. J Cell Sci 121, 1750-1757.
18. Dempsey GT, Vaughan JC, Chen KH, Bates M, Zhuang X (2011). Evaluation of fuorophores for optimal performance in localization-based super-resolution imaging. Nat Methods 8, 1027-1036.
19. Endres NF, Das R, Smith AW, Arkhipov A, Kovacs E, Huang Y, Pelton JG, Shan Y, Shaw DE, Wemmer DE, et al. (2013). Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 152, 543-556.
20. Forney GD (1973). The Viterbi algorithm. Proc IEEE 61, 268-278.
21. Gan HK, Kaye AH, Luwor RB (2009). The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 16, 748-754.
22. Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, Settleman J, Haber DA (2008). The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther 7, 874-879.
23. Greulich H, Chen T-H, Feng W, Jänne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, et al. (2005). Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med 2, e313.
24. Hanold LE, Oruganty K, Ton NT, Beedle AM, Kannan N, Kennedy EJ (2015a). Inhibiting EGFR dimerization using triazolyl-bridged dimeriza-tion arm mimics. PLoS One 10, e0118796.
25. Hanold LE, Watkins C P, Ton NT, Liaw P, Beedle AM, Kennedy EJ (2015b). Design of a selenylsulfde-bridged EGFR dimerization arm mimic. Bioorg Med Chem 23, 2761-2766.
26. Heilemann M, Linde S, Schüttpelz M, Kasper R, Seefeldt B, Mukherjee A, Tinnefeld P, Sauer M (2008). Subdiffraction-resolution fuorescence imaging with conventional fuorescent probes. Angew Chem Int Ed Engl 47, 6172-6176.
27. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D (2003). Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Cancer Res 63, 1130-1137.
28. Jiang J, Greulich H, Jänne PA, Sellers WR, Meyerson M, Griffn JD (2005). Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces Geftinib-sensitive cell cycle progression. Cancer Res 65, 8968-8974.
29. Jura N, Endres NF, Engel K, Deindl S, Das R, Lamers MH, Wemmer DE, Zhang X, Kuriyan J (2009). Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 137, 1293-1307.
30. Kästner J, Loeffer HH, Roberts SK, Martin-Fernandez ML, Winn MD (2009). Ectodomain orientation, conformational plasticity and oligomerization of ErbB1 receptors investigated by molecular dynamics. J Struct Biol 167, 117-128.
31. Kaszuba K, Grzybek M, Orłowski A, Danne R, Róg T, Simons K, Coskun Ü, Vattulainen I (2015). N-glycosylation as determinant of epidermal growth factor receptor conformation in membranes. Proc Natl Acad Sci USA 112, 4334-4339.
32. Keating E, Nohe A, Petersen NO (2008). Studies of distribution, location and dynamic properties of EGFR on the cell surface measured by image correlation spectroscopy. Eur Biophys J 37, 469-481.
33. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005). EGFR mutation and resistance of non-small-cell lung cancer to geftinib. N Engl J Med 352, 786-792.
34. Kozer N, Barua D, Henderson C, Nice EC, Burgess AW, Hlavacek WS, Clayton AH (2014). Recruitment of the adaptor protein Grb2 to EGFR tetramers. Biochemistry 53, 2594-2604.
35. Kozer N, Barua D, Orchard S, Nice EC, Burgess AW, Hlavacek WS, Clayton AH (2013). Exploring higher-order EGFR oligomerisation and phos-phorylation-a combined experimental and theoretical approach. Mol Biosyst 9, 1849-1863.
36. Kozer N, Henderson C, Jackson JT, Nice EC, Burgess AW, Clayton AHA (2011). Evidence for extended YFP-EGFR dimers in the absence of ligand on the surface of living cells. Phys Biol 8, 066002.
37. Kucherak OA, Oncul S, Darwich Z, Yushchenko DA, Arntz Y, Didier P, Mély Y, Klymchenko AS (2010). Switchable Nile Red-based probe for cholesterol and lipid order at the outer leafet of biomembranes. J Am Chem Soc 132, 4907-4916.
38. Lemmon MA, Schlessinger J (2010). Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134.
39. Lidke DS, Lidke KA, Rieger B, Jovin TM, Arndt-Jovin DJ (2005). Reaching out for signals: flopodia sense EGF and respond by directed retrograde transport of activated receptors. J Cell Biol 170, 619-626.
40. Lidke DS, Nagy P, Barisas BG, Heintzmann R, Post JN, Lidke KA, Clayton AHA, Arndt-Jovin DJ, Jovin TM (2003). Imaging molecular interactions in cells by dynamic and static fuorescence anisotropy (rFLIM and emFRET). Biochem Soc Trans 31, 1020-1027.
41. Lidke DS, Nagy P, Heintzmann R, Arndt-Jovin DJ, Post JN, Grecco HE, Jares-Erijman EA, Jovin TM (2004). Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat Biotechnol 22, 198-203.
42. Li S, Kussie P, Ferguson KM (2008). Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure 16, 216-227.
43. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJW, Kussie P, Ferguson KM (2005). Structural basis for inhibition of the epidermal growth factor receptor by Cetuximab. Cancer Cell 7, 301-311.
44. Low-Nam ST, Lidke KA, Cutler PJ, Roovers RC, van Bergen en Henegouwen PMP, Wilson BS, Lidke DS (2011). ErbB1 dimerization is promoted by domain co-confnement and stabilized by ligand binding. Nat Struct Mol Biol 18, 1244-1249.
45. Lu C, Mi L-Z, Grey MJ, Zhu J, Graef E, Yokoyama S, Springer TA (2010). Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor. Mol Cell Biol 30, 5432-5443.
46. Lu C, Mi L-Z, Schürpf T, Walz T, Springer TA (2012). Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor. J Biol Chem 287, 38244-38253.
47. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N Engl J Med 350, 2129-2139.
48. Macdonald JL, Pike LJ (2008). Heterogeneity in EGF-binding affnities arises from negative cooperativity in an aggregating system. Proc Natl Acad Sci USA 105, 112-117.
49. Macdonald-Obermann JL, Pike LJ (2009). The intracellular juxtamembrane domain of the epidermal growth factor (EGF) receptor is responsible for the allosteric regulation of EGF binding. J Biol Chem 284, 13570-13576.
50. Martin-Fernandez ML, Clarke DT, Tobin MJ, Jones SV, Jones GR (2002). Preformed oligomeric epidermal growth factor receptors undergo an ectodomain structure change during signaling. Biophys J 82, 2415-2427.
51. Mattoon D, Klein P, Lemmon MA, Lax I, Schlessinger J (2004). The tethered confguration of the EGF receptor extracellular domain exerts only a limited control of receptor function. Proc Natl Acad Sci USA 101, 923-928.
52. McLaughlin S, Smith SO, Hayman MJ, Murray D (2005). An electrostatic engine model for autoinhibition and activation of the epidermal growth factor receptor (EGFR/ErbB) family. J Gen Physiol 126, 41-53.
53. Mi L-Z, Grey MJ, Nishida N, Walz T, Lu C, Springer TA (2008). Functional and structural stability of the epidermal growth factor receptor in detergent micelles and phospholipid nanodiscs. Biochemistry 47, 10314-10323.
54. Mi L-Z, Lu C, Li Z, Nishida N, Walz T, Springer TA (2011). Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor. Nat Struct Mol Biol 18, 984-989.
55. Nagy P, Claus J, Jovin TM, Arndt-Jovin DJ (2010). Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis. Proc Natl Acad Sci USA 107, 16524-16529.
56. Needham SR, Hirsch M, Rolfe DJ, Clarke DT, Zanetti-Domingues LC, Wareham R, Martin-Fernandez ML (2013). Measuring EGFR separations on cells with ∼10 nm resolution via fuorophore localization imaging with photobleaching. PLoS One 8, e62331.
57. Needham SR, Zanetti-Domingues LC, Hirsch M, Rolfe DJ, Tynan CJ, Roberts SK, Martin-Fernandez ML, Clarke DT (2014). Structure-function relationships and supramolecular organization of the EGFR (epidermal growth factor receptor) on the cell surface. Biochem Soc Trans 42, 114-119.
58. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim J-H, Saito K, Sakamoto A, Inoue M, Shirouzu M, et al. (2002). Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110, 775-787.
59. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to geftinib therapy. Science 304, 1497-1500.
60. Pao W, Chmielecki J (2010). Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10, 760-774.
61. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005). Acquired resistance of lung adenocarcinomas to geftinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2, e73.
62. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al. (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to geftinib and erlotinib. Proc Natl Acad Sci USA 101, 13306-13311.
63. Red-Brewer ML, Choi SH, Alvarado D, Moravcevic K, Pozzi A, Lemmon MA, Carpenter G (2009). The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell 34, 641-651.
64. Red-Brewer ML, Yun C-H, Lai D, Lemmon MA, Eck MJ, Pao W (2013). Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proc Natl Acad Sci USA 110, E3595-E3604.
65. Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R (2008). Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol 47, 9-19.
66. Sako Y, Minoghchi S, Yanagida T (2000). Single-molecule imaging of EGFR signalling on the surface of living cells. Nat Cell Biol 2, 168-172.
67. Schlessinger J (2002). Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110, 669-672.
68. Schmiedel J, Blaukat A, Li S, Knöchel T, Ferguson KM (2008). Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 13, 365-373.
69. Schwartz SL, Yan Q, Telmer CA, Lidke KA, Bruchez M P, Lidke DS (2015). Fluorogen-activating proteins provide tunable labeling densities for tracking Fc?RI independent of IgE. ACS Chem Biol 10, 539-546.
70. Semrau S, Holtzer L, González-Gaitán M, Schmidt T (2011). Quantifcation of biological interactions with particle image cross-correlation spectros-copy (PICCS). Biophys J 100, 1810-1818.
71. Sengupta P, Jovanovic-Talisman T, Skoko D, Renz M, Veatch SL, Lippincott-Schwartz J (2011). Probing protein heterogeneity in the plasma membrane using PALM and pair correlation analysis. Nat Methods 8, 969-975.
72. Shan Y, Eastwood M P, Zhang X, Kim ET, Arkhipov A, Dror RO, Jumper J, Kuriyan J, Shaw DE (2012). Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell 149, 860-870.
73. Sharma SV, Bell DW, Settleman J, Haber D a (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7, 169-181.
74. Shelby SA, Holowka D, Baird B, Veatch SL (2013). Distinct stages of stimulated FceRI receptor clustering and immobilization are identifed through superresolution imaging. Biophys J 105, 2343-2354.
75. Smith CS, Joseph N, Rieger B, Lidke KA (2010). Fast, single-molecule localization that achieves theoretically minimum uncertainty. Nat Methods 7, 373-375.
76. Steinkamp M P, Low-Nam ST, Yang S, Lidke KA, Lidke DS, Wilson BS (2014). erbB3 is an active tyrosine kinase capable of homo-and heterointerac-tions. Mol Cell Biol 34, 965-977.
77. Talavera A, Friemann R, Gómez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, López-Requena A, Pupo A, Johansen RF, Sánchez O, et al. (2009). Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 69, 5851-5859.
78. Tanaka KAK, Suzuki KGN, Shirai YM, Shibutani ST, Miyahara MSH, Tsuboi H, Yahara M, Yoshimura A, Mayor S, Fujiwara TK, et al. (2010). Membrane molecules mobile even after chemical fxation. Nat Methods 7, 865-866.
79. Thiel KW, Carpenter G (2007). Epidermal growth factor receptor juxtamem-brane region regulates allosteric tyrosine kinase activation. Proc Natl Acad Sci USA 104, 19238-19243.
80. Tynan CJ, Roberts SK, Rolfe DJ, Clarke DT, Loeffer HH, Kästner J, Winn MD, Parker PJ, Martin-Fernandez ML (2011). Human epidermal growth factor receptor (EGFR) aligned on the plasma membrane adopts key features of Drosophila EGFR asymmetry. Mol Cell Biol 31, 2241-2252.
81. Valley CC, Lidke KA, Lidke DS (2014). The spatiotemporal organization of ErbB receptors: insights from microscopy. Cold Spring Harb Perspect Biol 6, a020735.
82. Van de Linde S, Löschberger A, Klein T, Heidbreder M, Wolter S, Heilemann M, Sauer M (2011). Direct stochastic optical reconstruction microscopy with standard fuorescent probes. Nat Protoc 6, 991-1009.
83. Veatch SL, Machta BB, Shelby SA, Chiang EN, Holowka DA, Baird BA (2012). Correlation functions quantify super-resolution images and estimate apparent clustering due to over-counting. PLoS One 7, e31457.
84. Wang Z, Longo Pa, Tarrant MK, Kim K, Head S, Leahy DJ, Cole PA (2011). Mechanistic insights into the activation of oncogenic forms of EGF receptor. Nat Struct Mol Biol 18, 1388-1393.
85. Webb SED, Roberts SK, Needham SR, Tynan CJ, Rolfe DJ, Winn MD, Clarke DT, Barraclough R, Martin-Fernandez ML (2008). Single-molecule imaging and fuorescence lifetime imaging microscopy show different structures for high-and low-affnity epidermal growth factor receptors in A431 cells. Biophys J 94, 803-819.
86. Yun C-H, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ (2007). Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11, 217-227.
87. Yun C-H, Mengwasser KE, Toms A V, Woo MS, Greulich H, Wong K-K, Meyerson M, Eck MJ (2008). The T790M mutation in EGFR kinase causes drug resistance by increasing the affnity for ATP. Proc Natl Acad Sci USA 105, 2070-2075.
88. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006). An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-1149.
89. Ziomkiewicz I, Loman A, Klement R, Fritsch C, Klymchenko AS, Bunt G, Jo-vin TM, Arndt-Jovin DJ (2013). Dynamic conformational transitions of the EGF receptor in living mammalian cells determined by FRET and fuorescence lifetime imaging microscopy. Cytometry A 83, 794-805.